GOG-3101 MK-2870-020 for cervical cancer - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called MK-2870 (the study drug) is a safe and effective option for people with cervical cancer. We want to see how well it works compared to the standard treatment for this diagnosis.
What is the Condition Being Studied?
Cervical Cancer
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
- Have cancer that is metastatic (has spread) or has returned after treatment
- Have received at least one previous line of treatment that included an anti-PD-1/anti-PD-L1 therapy
For more information about this study, contact the study team at patricia.vaudo@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 parts.
If you are in Part 1 of the study, you will take the study drug. If you are in Part 2 of the study, you will get another random assignment to 1 of 2 groups:
- If you are in Group 1, you will take the study drug.
- If you are in Group 2, you will receive the standard therapy that the study doctor believes is best for you. The standard drugs used to treat your form of cancer include: pemetrexed, tisotumab vedotin, topotecan, vinorelbine, gemcitabine, and irinotecan.
Study Details
Full Title
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to
Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of
Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic
Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
Principal Investigator
Angeles Alvarez Secord, MD, MHSc
Gynecologic Oncologist
Protocol Number
IRB:
PRO00115757
NCT:
NCT06459180
Phase
Phase
III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-684-3780